Search
forLearn
5 / 801 resultslearn guarana
learn vitamin b3
learn acetyl tetrapeptide-3
learn Glycine
Research
5 / 445 results
research 440 Topical application of anti-cancer drug Bortezomib stimulates proliferation of follicular cells and induces expression of hair keratins via GATA-3 transcription factor
Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
research GATA3 inhibits proliferation and induces expression of both early and late differentiation markers in keratinocytes of the human epidermis
research Decreased GATA3 levels cause changed mouse cutaneous innate lymphoid cell fate, facilitating hair follicle recycling
Lower GATA3 levels in mice help hair regrow by changing certain immune cells.
research Defining BMP functions in the hair follicle by conditional ablation of BMP receptor IA
BMP receptor IA is essential for proper hair cell differentiation in mice.
research A case of trichogerminoma: a rare cutaneous follicular neoplasm
Trichogerminoma is a rare, benign skin tumor from hair cells, with a small risk of becoming cancerous.
Community Join
5 / 1000+ resultscommunity This is an 8 week difference. Is this progress of any sort?
The user experienced significant hair regrowth over 8 weeks using oral Minoxidil and Dutasteride, noting healthier and denser hair. They reported no side effects and emphasized the importance of staying consistent with the treatment despite initial shedding.
community Where is GT20029 already? Grrrr
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Any updates or news on Gt20029?
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.